Literature DB >> 18478337

Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk.

Darren Tse1, Rihong Zhai, Wei Zhou, Rebecca S Heist, Kofi Asomaning, Li Su, Thomas J Lynch, John C Wain, David C Christiani, Geoffrey Liu.   

Abstract

PURPOSE: Functional variation in DNA repair capacity through single nucleotide polymorphisms (SNPs) of key repair genes is associated with a higher risk of developing various types of cancer. Studies have focused on the nucleotide excision repair (NER) and base excision repair (BER) pathways. We investigated whether variant alleles in seven SNPs within these pathways increased the risk of esophageal adenocarcinoma.
METHODS: DNA was extracted from prospectively collected blood specimens. The samples were genotyped for SNPs in NER genes (XPD Lys751Gln, XPD Asp312Asn, ERCC1 8092C/A, and ERCC1 118C/T), and BER genes (XRCC1 Arg399Gln, APE1 Asp148Glu, and hOGG1 Ser326Cys). The presence of variant alleles was correlated with risk of esophageal adenocarcinoma both individually and jointly.
RESULTS: Variant alleles in NER SNPs XPD Lys751Gln (AOR = 1.50, 95% CI 1.1-2.0), ERCC1 8092 C/A (AOR = 1.44, 95% CI 1.1-1.9), and ERCC1 118C/T (AOR = 1.42, 95% CI 1.0-1.9) were individually associated with esophageal adenocarcinoma risk. An increasing number of variant alleles in NER SNPs showed a significant trend with esophageal adenocarcinoma risk (p = 0.007).
CONCLUSIONS: The presence of variant alleles in NER genes increases risk of esophageal adenocarcinoma. There is evidence of an additive role for SNPs along a common DNA repair pathway. Future larger studies of esophageal adenocarcinoma etiology should evaluate entire biological pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18478337      PMCID: PMC3106102          DOI: 10.1007/s10552-008-9171-4

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  45 in total

1.  Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells.

Authors:  E J Duell; J K Wiencke; T J Cheng; A Varkonyi; Z F Zuo; T D Ashok; E J Mark; J C Wain; D C Christiani; K T Kelsey
Journal:  Carcinogenesis       Date:  2000-05       Impact factor: 4.944

Review 2.  Gastroesophageal reflux disease and Barrett's esophagus.

Authors:  D A Katzka; A K Rustgi
Journal:  Med Clin North Am       Date:  2000-09       Impact factor: 5.456

Review 3.  DNA repair gene status in oesophageal cancer.

Authors:  R Naidoo; R Chetty
Journal:  Mol Pathol       Date:  1999-06

4.  Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer: a case-control analysis in a Chinese population.

Authors:  Zhibin Hu; Liang Xu; Minhua Shao; Jing Yuan; Yi Wang; Feng Wang; Wentao Yuan; Ji Qian; Hongxia Ma; Ying Wang; Hongliang Liu; Weihong Chen; Lin Yang; Guangfu Jing; Xiang Huo; Feng Chen; Li Jin; Qingyi Wei; Tangchun Wu; Daru Lu; Wei Huang; Hongbing Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

5.  ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

Authors:  Jérôme Viguier; Valérie Boige; Catherine Miquel; Marc Pocard; Bruno Giraudeau; Jean-Christophe Sabourin; Michel Ducreux; Alain Sarasin; Françoise Praz
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

6.  Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study.

Authors:  Q Wei; L Cheng; C I Amos; L E Wang; Z Guo; W K Hong; M R Spitz
Journal:  J Natl Cancer Inst       Date:  2000-11-01       Impact factor: 13.506

7.  The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden.

Authors:  Weimin Ye; Rajiv Kumar; Gabriela Bacova; Jesper Lagergren; Kari Hemminki; Olof Nyrén
Journal:  Carcinogenesis       Date:  2006-03-29       Impact factor: 4.944

8.  Association of an ERCC1 polymorphism with adult-onset glioma.

Authors:  P Chen; J Wiencke; K Aldape; A Kesler-Diaz; R Miike; K Kelsey; M Lee; J Liu; M Wrensch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-08       Impact factor: 4.254

9.  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.

Authors:  David J Park; Wu Zhang; Jan Stoehlmacher; Denice Tsao-Wei; Susan Groshen; Ji Gil; Jim Yun; Erin Sones; Nalin Mallik; Heinz-Josef Lenz
Journal:  Clin Adv Hematol Oncol       Date:  2003-03

10.  Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma.

Authors:  Alan G Casson; Zuoyu Zheng; Susan C Evans; Paul J Veugelers; Geoffrey A Porter; Duane L Guernsey
Journal:  Carcinogenesis       Date:  2005-05-05       Impact factor: 4.944

View more
  43 in total

1.  XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls.

Authors:  Ling Yuan; Dan Cui; Er-Jiang Zhao; Chen-Zhi Jia; Li-Dong Wang; Wei-Quan Lu
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Comprehensive analysis of the correlation between base-excision repair gene SNPs and esophageal squamous cell carcinoma risk in a Chinese Han population.

Authors:  Yu Pu; Liang Zhao; Nan Dai; Mingfang Xu
Journal:  Mol Clin Oncol       Date:  2020-06-09

Review 3.  Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk.

Authors:  Chuan Liu; Qinghua Yin; Jianbing Hu; Jie Weng; Yajie Wang
Journal:  Tumour Biol       Date:  2013-09-06

4.  Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.

Authors:  Mi-Sun Lee; Chen-yu Liu; Li Su; David C Christiani
Journal:  Lung Cancer       Date:  2015-05-11       Impact factor: 5.705

5.  XPD Asp312Asn polymorphism and esophageal cancer risk: an update meta-analysis based on 3928 cases and 6012 controls.

Authors:  Xu-Feng Guo; Jun Wang; Xiao-Fei Lei; Yan-Ping Zeng; Xiao-Guang Lv; Wei-Guo Dong
Journal:  Int J Clin Exp Med       Date:  2014-09-15

Review 6.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.

Authors:  Ravindran Caspa Gokulan; Monica T Garcia-Buitrago; Alexander I Zaika
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-05-30       Impact factor: 10.680

7.  XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.

Authors:  Xin Zhang; Li-Peng Jiang; Yu Yin; Ya-Di Wang
Journal:  Tumour Biol       Date:  2014-03-04

8.  Current evidences on the XPG Asp1104His polymorphism and melanoma susceptibility: a meta-analysis based on case-control studies.

Authors:  Yuanzhi Xu; Guangjun Jiao; Li Wei; Ning Wang; Yajun Xue; Jin Lan; Yajie Wang; Chuan Liu; Meiqing Lou
Journal:  Mol Genet Genomics       Date:  2014-09-18       Impact factor: 3.291

9.  Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.

Authors:  Penelope A Bradbury; Matthew H Kulke; Rebecca S Heist; Wei Zhou; Clement Ma; Wei Xu; Ariela L Marshall; Rihong Zhai; Susanne M Hooshmand; Kofi Asomaning; Li Su; Frances A Shepherd; Thomas J Lynch; John C Wain; David C Christiani; Geoffrey Liu
Journal:  Pharmacogenet Genomics       Date:  2009-08       Impact factor: 2.089

10.  A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.

Authors:  Fang Wen; Zhiyong Zhao; Chuan Liu; Qinghua Yin; Jie Weng; Yajie Wang; Yuchen Ma
Journal:  Tumour Biol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.